Understanding the complex interactions between the various pathways disrupted in polycystic kidney and liver disease is essential to identify and optimize therapies for these disorders. Studies published in the past year have demonstrated a functional interaction between the main proteins implicated in these diseases and identified novel therapeutic approaches.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fedeles, S. V. et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat. Genet. 43, 639–647 (2011).
Reif, G. A. et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl− secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am. J. Physiol. Renal Physiol. 301, F1005–F1013 (2011).
Higashihara, E. et al. for the TEMPOFormula and 156-05-002 Study Investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin. J. Am. Soc. Nephrol. 6, 2499–2507 (2011).
Takiar, V. et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl Acad. Sci. USA 108, 2462–2467 (2011).
Yoshihara, D. et al. PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am. J. Physiol. Renal Physiol. 300, F465–F474 (2011).
Blazer-Yost, B. L. et al. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Res. 2010, 274376 (2010).
Karihaloo, A. et al. Macrophages promote cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 22, 1809–1814 (2011).
Talbot, J. J. et al. Polycystin-1 regulates STAT activity by a dual mechanism. Proc. Natl Acad. Sci. USA 108, 7985–7990 (2011).
Takakura, A. et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum. Mol. Genet. 20, 4143–4154 (2011).
Leonhard, W. N. et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am. J. Physiol. Renal Physiol. 300, F1193–F1202 (2011).
Acknowledgements
V. E. Torres and P. C. Harris are supported by the NIH grant DK090728.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V. E. Torres has received a grant from Otsuka Pharmaceuticals. P. C. Harris declares no competing interests.
Rights and permissions
About this article
Cite this article
Torres, V., Harris, P. Connecting the dots toward a polycystic kidney disease therapy. Nat Rev Nephrol 8, 66–68 (2012). https://doi.org/10.1038/nrneph.2011.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.196
This article is cited by
-
The importance of total kidney volume in evaluating progression of polycystic kidney disease
Nature Reviews Nephrology (2016)
-
Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—A KDIGO consensus report
Kidney International (2015)
-
Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1 -deficient mice
Kidney International (2014)
-
Novel insights into TRPV4 function in the kidney
Pflügers Archiv - European Journal of Physiology (2013)
